Methods: 18 patients with mild and 19 with moderate forms of hypertension were studied.
Nebivolol (“Nebilet” preparation,“Berlin-Chemi” firm) was adminestered in the dose of 5 mg …

The aim of the study was to assess the efficacy and tolerability of nebivolol in hypertensive
patients. 30 patients (22 men and 8 women) with mild/moderate hypertension were …

Background Nebivolol represents a therapeutic class of beta blockers with high beta 1
selectivity and modulatory effect on vascular reactions by releasing nitric oxide (NO) from …

2. Results During nebivolol treatment, significant (p< 0.000 I) decreases occurred in systolic
and diastolic blood pressure and heart rate. In the supine position, systolic blood pressure …

Nebivolol is a lipophilic beta 1-blocker. It is devoid of intrinsic sympathomimetic or
membrane stabilising activity but appears to have nitric oxide-mediated vasodilatory effects …

Background: The antihypertensive activity of beta-blockers generally increases during the
first 6 to 8 weeks of treatment; however, no study has systematically assessed whether blood …

This randomised double-blind placebo-controlled study investigated the effects of nebivolol
on blood pressure, plasma hormones [renin, aldosterone and atrial natriuretic peptide …

This review describes the main issues related to the use of nebivolol in patients with arterial
hypertension (AH). The features of nebivolol are discussed in detail, as it is highly selective …

Nebivolol is a cardioselective lipophilic β-blocker devoid of intrinsic sympathomimetic and
membrane-stabilizing actions. The pharmacological profile differs from that of conventional …

Background: Nebivolol is a third-generation highly selective b1-blocker with additional
endothelial nitric oxide (NO) mediated vasodilating activity. This property may potentiate the …